HDL and cardiovascular disease

Stephen J. Nicholls, Adam J. Nelson

Research output: Contribution to journalReview ArticleOtherpeer-review

4 Citations (Scopus)

Abstract

High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.

Original languageEnglish
Pages (from-to)142-147
Number of pages6
JournalPathology
Volume51
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Keywords

  • atherosclerosis
  • cardiovascular risk
  • clinical trials
  • HDL
  • lipids

Cite this

Nicholls, Stephen J. ; Nelson, Adam J. / HDL and cardiovascular disease. In: Pathology. 2019 ; Vol. 51, No. 2. pp. 142-147.
@article{0c87ec808c0d4672b029259e1ccc14c3,
title = "HDL and cardiovascular disease",
abstract = "High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.",
keywords = "atherosclerosis, cardiovascular risk, clinical trials, HDL, lipids",
author = "Nicholls, {Stephen J.} and Nelson, {Adam J.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.pathol.2018.10.017",
language = "English",
volume = "51",
pages = "142--147",
journal = "Pathology",
issn = "0031-3025",
publisher = "Elsevier",
number = "2",

}

HDL and cardiovascular disease. / Nicholls, Stephen J.; Nelson, Adam J.

In: Pathology, Vol. 51, No. 2, 01.02.2019, p. 142-147.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - HDL and cardiovascular disease

AU - Nicholls, Stephen J.

AU - Nelson, Adam J.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.

AB - High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.

KW - atherosclerosis

KW - cardiovascular risk

KW - clinical trials

KW - HDL

KW - lipids

UR - http://www.scopus.com/inward/record.url?scp=85059137508&partnerID=8YFLogxK

U2 - 10.1016/j.pathol.2018.10.017

DO - 10.1016/j.pathol.2018.10.017

M3 - Review Article

VL - 51

SP - 142

EP - 147

JO - Pathology

JF - Pathology

SN - 0031-3025

IS - 2

ER -